2017 Step Therapy (ST) Criteria

Size: px
Start display at page:

Download "2017 Step Therapy (ST) Criteria"

Transcription

1 2017 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that needs step therapy pre-approval. Below you will find a table of drugs that require step therapy pre-approval. If you find your drug on this list, talk to your doctor about what other drugs you could try first. To see if your drug is on the list refer to the index located at the end of this document for the medication you are looking for.

2 ANTIDIABETICS Products Affected Step 1: metformin 1,000 mg tablet metformin 500 mg tablet metformin 850 mg tablet metformin ER 1,000 mg 24 hr tablet,extended release metformin ER 1,000 mg tablet,extended release 24hr metformin ER 500 mg 24 hr tablet,extended release Step 2: Actoplus Met XR 15 mg-1,000 mg tablet,extended release Details metformin ER 500 mg tablet,extended metformin ER 500 mg tablet,extended release 24hr metformin ER 750 mg tablet,extended pioglitazone 15 mg-metformin 500 mg tablet pioglitazone 15 mg-metformin 850 mg tablet Actoplus Met XR 30 mg-1,000 mg tablet,extended release Cycloset 0.8 mg tablet Criteria As per the protocol, the member's electronic medication profile will be reviewed over the prior 90 days. If the profile shows that the member has had previous history of generic Metformin containing product, then the member has met the criteria for coverage of Cycloset and/or ACTOPLUS MET XR at the applicable copayment/coinsurance. 1

3 COREG CR Products Affected Step 1: carvedilol 12.5 mg tablet carvedilol 25 mg tablet Step 2: Coreg CR 10 mg capsule, extended release Coreg CR 20 mg capsule, extended release Details carvedilol mg tablet carvedilol 6.25 mg tablet Coreg CR 40 mg capsule, extended release Coreg CR 80 mg capsule, extended release Criteria As per the protocol, the member's electronic medication profile will be reviewed over the prior 90 days. If the profile shows that the member has had previous history of generic Carvedilol, then the member has met the criteria for coverage of Brand Coreg CR at the applicable copayment/coinsurance. 2

4 ELIDEL Products Affected Step 1: alclometasone 0.05 % topical cream alclometasone 0.05 % topical ointment amcinonide 0.1 % lotion amcinonide 0.1 % topical cream amcinonide 0.1 % topical ointment betamethasone dipropionate 0.05 % lotion betamethasone dipropionate 0.05 % topical cream betamethasone dipropionate 0.05 % topical ointment betamethasone valerate 0.1 % lotion betamethasone valerate 0.1 % topical cream betamethasone valerate 0.1 % topical ointment betamethasone valerate 0.12 % topical foam betamethasone, augmented 0.05 % lotion betamethasone, augmented 0.05 % topical cream betamethasone, augmented 0.05 % topical gel betamethasone, augmented 0.05 % topical ointment clobetasol 0.05 % lotion clobetasol 0.05 % scalp solution clobetasol 0.05 % shampoo clobetasol 0.05 % topical foam clobetasol 0.05 % topical gel diflorasone 0.05 % topical ointment fluocinolone 0.01 % topical body oil fluocinolone 0.01 % topical cream fluocinolone 0.01 % topical solution fluocinolone % topical cream fluocinolone % topical ointment fluocinonide 0.05 % topical cream fluocinonide 0.05 % topical gel fluocinonide 0.05 % topical ointment fluocinonide 0.05 % topical solution fluocinonide 0.1 % topical cream Fluocinonide-E 0.05% topical cream fluticasone % topical ointment fluticasone 0.05 % lotion fluticasone 0.05 % topical cream halobetasol propionate 0.05 % topical cream halobetasol propionate 0.05 % topical ointment hydrocortisone 1 % topical cream hydrocortisone 1 % topical ointment hydrocortisone 2.5 % lotion hydrocortisone 2.5 % topical cream hydrocortisone 2.5 % topical ointment hydrocortisone butyrate 0.1 % topical ointment hydrocortisone butyrate 0.1 % topical solution hydrocortisone butyrate-emollient 0.1 % clobetasol 0.05 % topical ointment topical cream clobetasol-emollient 0.05 % topical cream hydrocortisone valerate 0.2 % topical desonide 0.05 % lotion cream desonide 0.05 % topical cream hydrocortisone valerate 0.2 % topical desonide 0.05 % topical ointment ointment desoximetasone 0.05 % topical cream mometasone 0.1 % topical cream desoximetasone 0.05 % topical gel mometasone 0.1 % topical ointment desoximetasone 0.05 % topical ointment mometasone 0.1 % topical solution desoximetasone 0.25 % topical cream prednicarbate 0.1 % topical cream desoximetasone 0.25 % topical ointment prednicarbate 0.1 % topical ointment diflorasone 0.05 % topical cream triamcinolone acetonide % lotion 3

5 triamcinolone acetonide % topical cream triamcinolone acetonide % topical ointment triamcinolone acetonide 0.1 % lotion triamcinolone acetonide 0.1 % topical cream triamcinolone acetonide 0.1 % topical ointment triamcinolone acetonide 0.5 % topical cream triamcinolone acetonide 0.5 % topical ointment Triderm 0.1 % topical cream Step 2: Elidel 1 % topical cream Details Criteria As per the protocol, the member's electronic medication profile will be reviewed over the prior 90 days. If the profile shows that the member has had previous history of one topical generic Corticosteroid, then the member has met the criteria for coverage of Elidel at the applicable copayment/coinsurance. 4

6 GLYBURIDE Products Affected Step 1: glimepiride 1 mg tablet glimepiride 2 mg tablet glimepiride 4 mg tablet glipizide 10 mg tablet glipizide 2.5 mg-metformin 250 mg tablet glipizide 2.5 mg-metformin 500 mg tablet glipizide 5 mg tablet glipizide 5 mg-metformin 500 mg tablet glipizide ER 10 mg tablet, extended Step 2: glyburide 1.25 mg tablet glyburide 1.25 mg-metformin 250 mg tablet glyburide 2.5 mg tablet glyburide 2.5 mg-metformin 500 mg tablet Details glipizide ER 2.5 mg tablet, extended glipizide ER 5 mg tablet, extended release 24 hr pioglitazone 30 mg-glimepiride 2 mg tablet pioglitazone 30 mg-glimepiride 4 mg tablet glyburide 5 mg tablet glyburide 5 mg-metformin 500 mg tablet glyburide micronized 1.5 mg tablet glyburide micronized 3 mg tablet glyburide micronized 6 mg tablet Criteria As per the protocol, the member's electronic medication profile will be reviewed over the prior 90 days. If the profile shows that the member has had previous history of one step one agent then the member has met the criteria for coverage of step 2 agent at the applicable copayment/coinsurance 5

7 IMMUNOMODULATORS Products Affected Step 1: Humira 10 mg/0.2 ml subcutaneous syringe kit Humira 20 mg/0.4 ml subcutaneous syringe kit Humira 40 mg/0.8 ml subcutaneous syringe kit Humira Pediatric Crohn's Starter 40 mg/0.8 ml subcutaneous syringe kit Step 2: Actemra 200 mg/10 ml (20 mg/ml) intravenous solution Actemra 400 mg/20 ml (20 mg/ml) intravenous solution Actemra 80 mg/4 ml (20 mg/ml) intravenous solution Humira Pediatric Crohn's Starter 40 mg/0.8 ml subcutaneous syringe kit (6 pack) Humira Pen 40 mg/0.8 ml subcutaneous Humira Pen Crohn's-Ulc Colitis-Hid Sup Starter 40 mg/0.8 ml subcut kit Humira Pen Psoriasis-Uveitis Starter 40 mg/0.8 ml subcutaneous kit Cimzia 400 mg/2 ml (200 mg/ml x 2) subcutaneous syringe kit Cimzia Powder for Recon 400 mg (200 mg x 2 vials) subcutaneous kit Xeljanz 5 mg tablet Xeljanz XR 11 mg tablet,extended release Details Criteria As per the protocol, the member's electronic medication profile will be reviewed over the prior 90 days. If the profile shows that the member has had previous history of Humira, then the member has met the criteria for coverage of Actemra, Xeljanz, Xeljanz XR or Cimzia at the applicable copayment/coinsurance. 6

8 OPHTHALMIC ANTIHISTAMINES Products Affected Step 1: epinastine 0.05 % eye drops Lastacaft 0.25 % eye drops olopatadine 0.1 % eye drops Step 2: Pataday 0.2 % eye drops olopatadine 0.2 % eye drops Pazeo 0.7 % eye drops Details Criteria As per the protocol, the member's electronic medication profile will be reviewed over the prior 90 days. If the profile shows that the member has had previous history of generic ophthalmic antihistamine, Lastacaft solution, or Pazeo then the member has met the criteria for coverage of Pataday solution at the applicable copayment/coinsurance. 7

9 OVERACTIVE BLADDER Products Affected Step 1: darifenacin ER 15 mg tablet,extended darifenacin ER 7.5 mg tablet,extended oxybutynin chloride 5 mg tablet oxybutynin chloride 5 mg/5 ml syrup oxybutynin chloride ER 10 mg tablet,extended oxybutynin chloride ER 15 mg tablet,extended Step 2: Gelnique 10 % (100 mg/gram) transdermal gel packet Details oxybutynin chloride ER 5 mg tablet,extended tolterodine 1 mg tablet tolterodine 2 mg tablet tolterodine ER 2 mg capsule,extended tolterodine ER 4 mg capsule,extended trospium 20 mg tablet trospium ER 60 mg capsule,extended Criteria As per the protocol, the member's electronic medication profile will be reviewed over the prior 90 days. If the profile shows that the member has had previous history of one step one agent then the member has met the criteria for coverage of step 2 agent at the applicable copayment/coinsurance 8

10 VOLTAREN GEL Products Affected Step 1: celecoxib 100 mg capsule celecoxib 200 mg capsule celecoxib 400 mg capsule celecoxib 50 mg capsule diclofenac 1 % topical gel diclofenac 50 mg-misoprostol 200 mcg tablet,immed.and delayed release diclofenac 75 mg-misoprostol 200 mcg tablet,immediate,delayed release diclofenac ER 100 mg tablet,extended diclofenac potassium 50 mg tablet diclofenac sodium 25 mg tablet,delayed release diclofenac sodium 50 mg tablet,delayed release diclofenac sodium 75 mg tablet,delayed release diflunisal 500 mg tablet etodolac 200 mg capsule etodolac 300 mg capsule etodolac 400 mg tablet etodolac 500 mg tablet etodolac ER 400 mg tablet,extended etodolac ER 500 mg tablet,extended etodolac ER 600 mg tablet,extended fenoprofen 600 mg tablet flurbiprofen 100 mg tablet flurbiprofen 50 mg tablet ibuprofen 100 mg/5 ml oral suspension Step 2: Voltaren 1 % topical gel ibuprofen 400 mg tablet ibuprofen 600 mg tablet ibuprofen 800 mg tablet ketoprofen 50 mg capsule ketoprofen 75 mg capsule ketoprofen ER 200 mg 24 hr capsule,extended release meclofenamate 100 mg capsule meclofenamate 50 mg capsule mefenamic acid 250 mg capsule meloxicam 15 mg tablet meloxicam 7.5 mg tablet nabumetone 500 mg tablet nabumetone 750 mg tablet Naprelan CR 750 mg tab,extended release 24 hr mphase naproxen 125 mg/5 ml oral suspension naproxen 250 mg tablet naproxen 375 mg tablet naproxen 375 mg tablet,delayed release naproxen 500 mg tablet naproxen 500 mg tablet,delayed release naproxen sodium 275 mg tablet naproxen sodium 550 mg tablet naproxen sodium ER 375 mg tablet,extended release 24hr mphase oxaprozin 600 mg tablet piroxicam 10 mg capsule piroxicam 20 mg capsule sulindac 150 mg tablet sulindac 200 mg tablet tolmetin 400 mg capsule tolmetin 600 mg tablet Details 9

11 Details Criteria As per the protocol, the member's electronic medication profile will be reviewed over the prior 90 days. If the profile shows that the member has had previous history of one step one agent then the member has met the criteria for coverage of step 2 agent at the applicable copayment/coinsurance 10

12 Index A Actemra 200 mg/10 ml (20 mg/ml) intravenous solution... 6 Actemra 400 mg/20 ml (20 mg/ml) intravenous solution... 6 Actemra 80 mg/4 ml (20 mg/ml) intravenous solution... 6 Actoplus Met XR 15 mg-1,000 mg tablet,extended release... 1 Actoplus Met XR 30 mg-1,000 mg tablet,extended release... 1 alclometasone 0.05 % topical cream... 3, 4 alclometasone 0.05 % topical ointment.. 3, 4 amcinonide 0.1 % lotion... 3, 4 amcinonide 0.1 % topical cream... 3, 4 amcinonide 0.1 % topical ointment... 3, 4 B betamethasone dipropionate 0.05 % lotion 3, 4 betamethasone dipropionate 0.05 % topical cream... 3, 4 betamethasone dipropionate 0.05 % topical betamethasone valerate 0.1 % lotion... 3, 4 betamethasone valerate 0.1 % topical cream... 3, 4 betamethasone valerate 0.1 % topical betamethasone valerate 0.12 % topical foam... 3, 4 betamethasone, augmented 0.05 % lotion3, 4 betamethasone, augmented 0.05 % topical cream... 3, 4 betamethasone, augmented 0.05 % topical gel... 3, 4 betamethasone, augmented 0.05 % topical C carvedilol 12.5 mg tablet... 2 carvedilol 25 mg tablet... 2 carvedilol mg tablet... 2 carvedilol 6.25 mg tablet... 2 celecoxib 100 mg capsule... 9, 10 celecoxib 200 mg capsule... 9, celecoxib 400 mg capsule... 9, 10 celecoxib 50 mg capsule... 9, 10 Cimzia 400 mg/2 ml (200 mg/ml x 2) subcutaneous syringe kit... 6 Cimzia Powder for Recon 400 mg (200 mg x 2 vials) subcutaneous kit... 6 clobetasol 0.05 % lotion... 3, 4 clobetasol 0.05 % scalp solution... 3, 4 clobetasol 0.05 % shampoo... 3, 4 clobetasol 0.05 % topical foam... 3, 4 clobetasol 0.05 % topical gel... 3, 4 clobetasol 0.05 % topical ointment... 3, 4 clobetasol-emollient 0.05 % topical cream 3, 4 Coreg CR 10 mg capsule, extended release 2 Coreg CR 20 mg capsule, extended release 2 Coreg CR 40 mg capsule, extended release 2 Coreg CR 80 mg capsule, extended release 2 Cycloset 0.8 mg tablet... 1 D darifenacin ER 15 mg tablet,extended... 8 darifenacin ER 7.5 mg tablet,extended... 8 desonide 0.05 % lotion... 3, 4 desonide 0.05 % topical cream... 3, 4 desonide 0.05 % topical ointment... 3, 4 desoximetasone 0.05 % topical cream... 3, 4 desoximetasone 0.05 % topical gel... 3, 4 desoximetasone 0.05 % topical ointment 3, 4 desoximetasone 0.25 % topical cream... 3, 4 desoximetasone 0.25 % topical ointment 3, 4 diclofenac 1 % topical gel... 9, 10 diclofenac 50 mg-misoprostol 200 mcg tablet,immed.and delayed release... 9, 10 diclofenac 75 mg-misoprostol 200 mcg tablet,immediate,delayed release... 9, 10 diclofenac ER 100 mg tablet,extended... 9, 10 diclofenac potassium 50 mg tablet... 9, 10 diclofenac sodium 25 mg tablet,delayed release... 9, 10 diclofenac sodium 50 mg tablet,delayed release... 9, 10

13 diclofenac sodium 75 mg tablet,delayed release... 9, 10 diflorasone 0.05 % topical cream... 3, 4 diflorasone 0.05 % topical ointment... 3, 4 diflunisal 500 mg tablet... 9, 10 E Elidel 1 % topical cream... 3, 4 epinastine 0.05 % eye drops... 7 etodolac 200 mg capsule... 9, 10 etodolac 300 mg capsule... 9, 10 etodolac 400 mg tablet... 9, 10 etodolac 500 mg tablet... 9, 10 etodolac ER 400 mg tablet,extended release 24 hr... 9, 10 etodolac ER 500 mg tablet,extended release 24 hr... 9, 10 etodolac ER 600 mg tablet,extended release 24 hr... 9, 10 F fenoprofen 600 mg tablet... 9, 10 fluocinolone 0.01 % topical body oil... 3, 4 fluocinolone 0.01 % topical cream... 3, 4 fluocinolone 0.01 % topical solution... 3, 4 fluocinolone % topical cream... 3, 4 fluocinolone % topical ointment... 3, 4 fluocinonide 0.05 % topical cream... 3, 4 fluocinonide 0.05 % topical gel... 3, 4 fluocinonide 0.05 % topical ointment... 3, 4 fluocinonide 0.05 % topical solution... 3, 4 fluocinonide 0.1 % topical cream... 3, 4 Fluocinonide-E 0.05% topical cream... 3, 4 flurbiprofen 100 mg tablet... 9, 10 flurbiprofen 50 mg tablet... 9, 10 fluticasone % topical ointment... 3, 4 fluticasone 0.05 % lotion... 3, 4 fluticasone 0.05 % topical cream... 3, 4 G Gelnique 10 % (100 mg/gram) transdermal gel packet... 8 glimepiride 1 mg tablet... 5 glimepiride 2 mg tablet... 5 glimepiride 4 mg tablet... 5 glipizide 10 mg tablet... 5 glipizide 2.5 mg-metformin 250 mg tablet. 5 glipizide 2.5 mg-metformin 500 mg tablet. 5 glipizide 5 mg tablet glipizide 5 mg-metformin 500 mg tablet... 5 glipizide ER 10 mg tablet, extended release 24 hr... 5 glipizide ER 2.5 mg tablet, extended release 24 hr... 5 glipizide ER 5 mg tablet, extended release 24 hr... 5 glyburide 1.25 mg tablet... 5 glyburide 1.25 mg-metformin 250 mg tablet... 5 glyburide 2.5 mg tablet... 5 glyburide 2.5 mg-metformin 500 mg tablet 5 glyburide 5 mg tablet... 5 glyburide 5 mg-metformin 500 mg tablet... 5 glyburide micronized 1.5 mg tablet... 5 glyburide micronized 3 mg tablet... 5 glyburide micronized 6 mg tablet... 5 H halobetasol propionate 0.05 % topical cream... 3, 4 halobetasol propionate 0.05 % topical Humira 10 mg/0.2 ml subcutaneous syringe kit... 6 Humira 20 mg/0.4 ml subcutaneous syringe kit... 6 Humira 40 mg/0.8 ml subcutaneous syringe kit... 6 Humira Pediatric Crohn's Starter 40 mg/0.8 ml subcutaneous syringe kit... 6 Humira Pediatric Crohn's Starter 40 mg/0.8 ml subcutaneous syringe kit (6 pack)... 6 Humira Pen 40 mg/0.8 ml subcutaneous... 6 Humira Pen Crohn's-Ulc Colitis-Hid Sup Starter 40 mg/0.8 ml subcut kit... 6 Humira Pen Psoriasis-Uveitis Starter 40 mg/0.8 ml subcutaneous kit... 6 hydrocortisone 1 % topical cream... 3, 4 hydrocortisone 1 % topical ointment... 3, 4 hydrocortisone 2.5 % lotion... 3, 4 hydrocortisone 2.5 % topical cream... 3, 4 hydrocortisone 2.5 % topical ointment... 3, 4 hydrocortisone butyrate 0.1 % topical hydrocortisone butyrate 0.1 % topical solution... 3, 4

14 hydrocortisone butyrate-emollient 0.1 % topical cream... 3, 4 hydrocortisone valerate 0.2 % topical cream... 3, 4 hydrocortisone valerate 0.2 % topical I ibuprofen 100 mg/5 ml oral suspension... 9, 10 ibuprofen 400 mg tablet... 9, 10 ibuprofen 600 mg tablet... 9, 10 ibuprofen 800 mg tablet... 9, 10 K ketoprofen 50 mg capsule... 9, 10 ketoprofen 75 mg capsule... 9, 10 ketoprofen ER 200 mg 24 hr capsule,extended release... 9, 10 L Lastacaft 0.25 % eye drops... 7 M meclofenamate 100 mg capsule... 9, 10 meclofenamate 50 mg capsule... 9, 10 mefenamic acid 250 mg capsule... 9, 10 meloxicam 15 mg tablet... 9, 10 meloxicam 7.5 mg tablet... 9, 10 metformin 1,000 mg tablet... 1 metformin 500 mg tablet... 1 metformin 850 mg tablet... 1 metformin ER 1,000 mg 24 hr tablet,extended release... 1 metformin ER 1,000 mg tablet,extended release 24hr... 1 metformin ER 500 mg 24 hr tablet,extended release... 1 metformin ER 500 mg tablet,extended... 1 metformin ER 500 mg tablet,extended release 24hr... 1 metformin ER 750 mg tablet,extended... 1 mometasone 0.1 % topical cream... 3, 4 mometasone 0.1 % topical ointment... 3, 4 mometasone 0.1 % topical solution... 3, 4 N nabumetone 500 mg tablet... 9, 10 nabumetone 750 mg tablet... 9, Naprelan CR 750 mg tab,extended release 24 hr mphase... 9, 10 naproxen 125 mg/5 ml oral suspension 9, 10 naproxen 250 mg tablet... 9, 10 naproxen 375 mg tablet... 9, 10 naproxen 375 mg tablet,delayed release 9, 10 naproxen 500 mg tablet... 9, 10 naproxen 500 mg tablet,delayed release 9, 10 naproxen sodium 275 mg tablet... 9, 10 naproxen sodium 550 mg tablet... 9, 10 naproxen sodium ER 375 mg tablet,extended release 24hr mphase. 9, 10 O olopatadine 0.1 % eye drops... 7 olopatadine 0.2 % eye drops... 7 oxaprozin 600 mg tablet... 9, 10 oxybutynin chloride 5 mg tablet... 8 oxybutynin chloride 5 mg/5 ml syrup... 8 oxybutynin chloride ER 10 mg tablet,extended... 8 oxybutynin chloride ER 15 mg tablet,extended... 8 oxybutynin chloride ER 5 mg tablet,extended... 8 P Pataday 0.2 % eye drops... 7 Pazeo 0.7 % eye drops... 7 pioglitazone 15 mg-metformin 500 mg tablet... 1 pioglitazone 15 mg-metformin 850 mg tablet... 1 pioglitazone 30 mg-glimepiride 2 mg tablet 5 pioglitazone 30 mg-glimepiride 4 mg tablet 5 piroxicam 10 mg capsule... 9, 10 piroxicam 20 mg capsule... 9, 10 prednicarbate 0.1 % topical cream... 3, 4 prednicarbate 0.1 % topical ointment... 3, 4 S sulindac 150 mg tablet... 9, 10 sulindac 200 mg tablet... 9, 10 T tolmetin 400 mg capsule... 9, 10 tolmetin 600 mg tablet... 9, 10 tolterodine 1 mg tablet... 8 tolterodine 2 mg tablet... 8

15 tolterodine ER 2 mg capsule,extended... 8 tolterodine ER 4 mg capsule,extended... 8 triamcinolone acetonide % lotion. 3, 4 triamcinolone acetonide % topical cream... 3, 4 triamcinolone acetonide % topical triamcinolone acetonide 0.1 % lotion... 3, 4 triamcinolone acetonide 0.1 % topical cream... 3, 4 triamcinolone acetonide 0.1 % topical triamcinolone acetonide 0.5 % topical cream... 3, 4 triamcinolone acetonide 0.5 % topical Triderm 0.1 % topical cream... 3, 4 trospium 20 mg tablet... 8 trospium ER 60 mg capsule,extended release 24 hr... 8 V Voltaren 1 % topical gel... 9, 10 X Xeljanz 5 mg tablet... 6 Xeljanz XR 11 mg tablet,extended release. 6 14

16 GuildNet Gold Plus FIDA Plan is a managed care plan that contracts with both Medicare and New York State Department of Health (Medicaid) to provide benefits of both programs to Participants through the Fully Integrated Duals Advantage (FIDA) Demonstration. Beneficiaries must use network pharmacies to access their premium and/or copayment/coinsurance may change on January 1, This document includes GuildNet Gold Plus FIDA Plan s partial formulary as of September 1, For a complete, updated formulary, please visit our website at or call (TTY ). For alternative formats or language, please call Participant Services toll free at: , Monday through Sunday from 8am to 8pm. TTY/TDD users should call You can get this information for free in other languages. Call and TTY/TDD during 8am to 8pm. The call is free. Usted puede obtener esta información en otros idiomas gratis. Llame al o TTY/TDD al , de lunes a domingo de 8am a 8pm. La llamada es gratis. Queste informazioni sono disponibili gratuitamente in altre lingue. Chiamare il numero verde o mediante un telefono testuale per non udenti (TTY/TDD), da lunedì a domenica, dalle 8 alle 20. La chiamata è gratuita. 您可以免費獲得本信息的其他語言版本 請撥打 或聽障 / 語障人士專線 (TTY/TDD) , 星期一至星期日上午 8 時至晚上 8 時 撥打該電話免費 Ou kapab jwenn enfòmasyon sa yo gratis nan lòt lang. Rele nimewo oswa TTY/TDD , lendi jiska dimanch, depi 8am jiska 8pm. Koutfil la gratis. 다른언어로작성된이정보를무료로얻으실수있습니다. 월요일 - 일요일오전 8 시부터오후 8 시사이에 번이나 TTY/TDD 번으로전화주세요. 통화는무료입니다. Вы можете бесплатно получить эту информацию на других языках. Позвоните по телефону и TTY/TDD Служба работает с понедельника по воскресенье с 08:00 до 20:00 ч. Звонок бесплатный. The State of New York has created a participant ombudsman program called the Independent Consumer Advocacy Network (ICAN) to provide Participants free, confidential assistance on any services offered by GuildNet Gold Plus FIDA Plan. ICAN may be reached toll-free at or online at icannys.org v16 15

2018 Step Therapy (ST) Criteria

2018 Step Therapy (ST) Criteria 2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a

More information

2018 Step Therapy (ST) Criteria

2018 Step Therapy (ST) Criteria 2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a

More information

2016 Step Therapy (ST) Criteria

2016 Step Therapy (ST) Criteria 2016 Step Therapy (ST) Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that

More information

2015 Step Therapy (ST) Criteria

2015 Step Therapy (ST) Criteria 2015 Step Therapy (ST) Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that

More information

2018 Step Therapy Criteria (List of Step Therapy Criteria)

2018 Step Therapy Criteria (List of Step Therapy Criteria) Criteria Last Updated: October 05, 2017 Effective Date: January 1, 2018 2018 Step Therapy Criteria (List of Step Therapy Criteria) PLEASE READ CAREFULLY: IEHP DUALCHOICE CAL MEDICONNECT PLAN (MEDICARE-

More information

2018 WPS MedicareRx Plan (PDP) Step Therapy

2018 WPS MedicareRx Plan (PDP) Step Therapy 2018 WPS MedicareRx Plan (PDP) Step Therapy In some cases, the WPS MedicareRx Plan (PDP) requires you to first try certain drugs to treat your medical condition before we will cover another drug for that

More information

2018 Step Therapy Criteria (List of Step Therapy Criteria)

2018 Step Therapy Criteria (List of Step Therapy Criteria) Step Therapy Criteria Last Updated: March 20, 2018 Effective Date: April 1, 2018 2018 Step Therapy Criteria (List of Step Therapy Criteria) PLEASE READ CAREFULLY: IEHP DUALCHOICE CAL MEDICONNECT PLAN (MEDICARE-MEDICAID

More information

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug

More information

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet

COLCRYS-PST. Products Affected Step 1: Mitigare 0.6 mg capsule. Details. Step 2: Colcrys 0.6 mg tablet COLCRYS-PST Mitigare 0.6 mg capsule Colcrys 0.6 mg tablet Criteria If the patient has tried one Step 1 product, authorization for a Step 2 product may be given. Exceptions can be made for a step 2 drug

More information

2014 Step Therapy Criteria (List of Step Therapy Criteria)

2014 Step Therapy Criteria (List of Step Therapy Criteria) Criteria Last Updated: November 1, 2014 2014 Step Therapy Criteria (List of Step Therapy Criteria) PLEASE READ CAREFULLY: IEHP MEDICARE DUALCHOICE (HMO SNP) REQUIRES YOU TO FIRST TRY CERTAIN DRUGS TO TREAT

More information

ALLERGIC RHINITIS-NASAL

ALLERGIC RHINITIS-NASAL ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step

More information

ALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal

ALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal ALZHEIMER'S DRUGS Products Affected Step 1: donepezil 10 mg disintegrating tablet donepezil 10 mg tablet donepezil 23 mg tablet donepezil 5 mg disintegrating tablet donepezil 5 mg tablet galantamine 12

More information

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs)

Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) CareAdvantage CMC 2018 Formulary Supplement II (List of Covered Drugs) Step Therapy Criteria (Criteria for Step Therapy-2 [ST-2] Drugs) Formulary ID: 00018157 Formulary Version:11 19 CMS Approved: 08/21/2018

More information

Neighborhood Medicaid Formulary Changes: June 2017

Neighborhood Medicaid Formulary Changes: June 2017 Neighborhood Medicaid Formulary Changes: June 2017 The following changes to the Neighborhood Medicaid Formulary were recently approved by the Pharmacy and Therapeutics (P&T) Committee. All changes were

More information

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017

More information

Spring 2016 Diabetes and Heart Disease Awareness

Spring 2016 Diabetes and Heart Disease Awareness Spring 2016 Diabetes and Heart Disease Awareness Molina Healthy Living with Diabetes and Heart Healthy Living In This Issue Control Your Blood Pressure... 1 Manage Your Diabetes... 2 Heart Disease... 2

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa

More information

Step Therapy Criteria 2019

Step Therapy Criteria 2019 Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)

More information

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details.

These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details. FlexRx Standard Utilization Management (PA, QL,) Updates January 1, 2018 How to use this drug list This drug list includes updates to Utilization Management (UM) programs. UM may include a prior authorization

More information

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

The safety and effectiveness of Dupixent in pediatric patients have not been established (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent

More information

2018 Medicare Part D Formulary Change

2018 Medicare Part D Formulary Change 2018 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017

More information

Effective for all members on August 1, 2017

Effective for all members on August 1, 2017 August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List

More information

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

2015 Step Therapy Prior Authorization Medical Necessity Guidelines Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet

More information

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017 Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017 Providers may call the Pharmacy Help Desk at 800-641-8921 for more information or questions about criteria. The formulary may change

More information

2017 Step Therapy Criteria

2017 Step Therapy Criteria FRESENIUS TOTAL HEALTH 2017 Step Therapy Updated 07/01/2017. For more recent information or other questions, please contact Fresenius Total Health Customer Service at 1-855-598-6774 / TTY 1-844-209-9094.

More information

Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria

Acyclovir Ointment. Aetna Better Health Pennsylvania. Products Affected. acyclovir ointment 5 % external Details. Criteria Medications that require Step Therapy (ST) require trial and failure of preferred formulary agents prior to their authorization. If the prerequisite medications have been filled within the specified time

More information

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir Acyclovir Ointment Mercy Care Plan acyclovir ointment 5 % external Requires use of oral Acyclovir 1 Adcirca ADCIRCA TABLET 20 MG ORAL Requires use of Sildenafil 2 Albenza ALBENZA TABLET 200 MG ORAL Requires

More information

2017 Medicare Part D Formulary Change

2017 Medicare Part D Formulary Change 2017 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy

More information

Step Therapy Medications

Step Therapy Medications Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG

More information

WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015)

WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015) WELLCARE/ OHANA HEALTH PLAN 2015 STEP THERAPY CRITERIA (No Changes Made Since: 08/2015) **To get updated information about the drugs covered by WellCare/ Ohana, please visit our website (https://www.wellcare.com

More information

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY

ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY South Country Health Alliance 2017 Step Therapy Formulary ID: 17431 Last Updated: 10/20/2017 Effective Date: 11-01-2017 ANGIOTENSIN RECEPTOR BLOCKERS STEP THERAPY BENICAR 20 MG BENICAR 40 MG BENICAR 5

More information

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) 2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) In some cases, UCare requires you to first try certain drugs to

More information

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so

More information

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+)

2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) 2018 STEP THERAPY CRITERIA UCare Connect (SNBC) MinnesotaCare Prepaid Medical Assistance Program (PMAP) Minnesota Senior Care Plus (MSC+) In some cases, UCare requires you to first try certain drugs to

More information

Dupixent (dupilumab)

Dupixent (dupilumab) Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

Pharmacologic Treatment of Atopic Dermatitis

Pharmacologic Treatment of Atopic Dermatitis J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc

More information

Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria

Mercy Care ALBENDAZOLE. Products Affected. ALBENZA TABLET 200 MG ORAL Details. Criteria. Refer to PA Guideline for approval criteria ALBENDAZOLE Mercy Care ALBENZA TABLET 200 MG ORAL Refer to PA Guideline for approval criteria 1 BRIMONIDINE-TIMOLOL COMBIGAN SOLUTION 0.2-0.5 % OPHTHALMIC Requires use of separate ingredients for at least

More information

2018 Step Therapy (ST) Criteria

2018 Step Therapy (ST) Criteria 2018 Step Therapy (ST) Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that

More information

2017 Step Therapy (ST) Criteria

2017 Step Therapy (ST) Criteria 2017 Step Therapy (ST) Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a drug that

More information

ALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017

ALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone 15 mg tablet alogliptin 12.5 mg-pioglitazone

More information

Memorial Hermann Advantage HMO February 2019 Formulary Addendum

Memorial Hermann Advantage HMO February 2019 Formulary Addendum Memorial Hermann Advantage HMO February 2019 Formulary Addendum Changes may have occurred since the printing of your current Memorial Hermann Advantage HMO Formulary. Medications that may have been added

More information

2013 Step Therapy (ST) Criteria

2013 Step Therapy (ST) Criteria 2013 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a

More information

2017 Medicare Part D Formulary Change

2017 Medicare Part D Formulary Change 2017 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy

More information

Advantage by Peach State Health Plan 2012 Prior Authorization Listing. Approved 10/23/2011 Effective October 2011

Advantage by Peach State Health Plan 2012 Prior Authorization Listing. Approved 10/23/2011 Effective October 2011 Advantage by Peach State Health Plan 2012 Approved 10/23/2011 Effective October 2011 Note to members: The prior authorization requirements are listed to provide you with information to discuss treatment

More information

ANTIDEPRESSANT THERAPY

ANTIDEPRESSANT THERAPY Step Therapy Paramount Medicare Enhanced Formulary 2011 Formulary ID 11110, Ver 23. CMS Approved 10-25-2011. Last Updated: 10-05-2011 ANTIDEPRESSANT THERAPY Celexa Pristiq Cymbalta Prozac Effexor Prozac

More information

ALLERGIC CONJUNCTIVITIS AGENTS

ALLERGIC CONJUNCTIVITIS AGENTS 2018 5 Tier Standard- Keystone First VIP Choice Document: 2018 Step Therapy Formulary ID: 18390 Last Updated: 04/2018 Effective Date: 05-01-2018 ALLERGIC CONJUNCTIVITIS AGENTS epinastine 0.05 % eye drops

More information

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION Added Prior Authorization 7/1/17 CORLANOR 5 MG TABLET Added Prior Authorization 7/1/17 CORLANOR 7.5 MG TABLET Added Prior Authorization 7/1/17

More information

2017 Formulary Changes Year to Date

2017 Formulary Changes Year to Date 2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or

More information

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.

More information

WellCare s South Carolina Preferred Drug List Update

WellCare s South Carolina Preferred Drug List Update WellCare s South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on 09/21/2017.

More information

TennCare Program TN MAC Price Change List As of: 03/30/2017

TennCare Program TN MAC Price Change List As of: 03/30/2017 1 TN List Run : 03/30/17 Old PRAZOSIN HCL 5 MG CAPSULE ORAL 03/29/2017 1.11209 1.12560 ( 1.2) CAPTOPRIL 12.5 MG TABLET ORAL 07/07/2015 1.07191 1.10416 ( 2.9) ISOSORBIDE DINITRATE 5 MG TABLET ORAL 03/29/2017

More information

ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018

ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018 Step Therapy Requirements Effective April 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone

More information

ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018

ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018 Step Therapy Requirements Effective June 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone

More information

High-Cost Drug Exclusions

High-Cost Drug Exclusions PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at

More information

2018 Step Therapy FID 18088

2018 Step Therapy FID 18088 2018 Step Therapy FID 18088 Step Therapy ANTIDEPRESSANTS, SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS LEON 2018 Desvenlafaxine Er Fetzima Fetzima Titration Pack Khedezla Paxil SUSP Pristiq Trintellix

More information

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details AMANTADINE ER OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE OSMOLEX ER 258 MG TABLET, PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.

More information

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017 VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 01/01/2017 Updated 12/23/2016 ANTICONVULSANTS Aptiom 200 mg tablet Potiga 200 mg tablet Aptiom 400 mg tablet Potiga 300 mg tablet Aptiom

More information

Step Therapy Medications

Step Therapy Medications Step Therapy Medications Step Therapy Group APTIOM Step-2: APTIOM 200 MG TABLET or APTIOM 400 MG TABLET or APTIOM 600 MG TABLET or APTIOM 800 MG TABLET Step 1 Drug(s): Oxcarbazepine immediate-release,

More information

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS ANTIDIABETIC AGENTS - MISCELLANEOUS Glyxambi 10 mg-5 mg tablet Glyxambi 25 mg-5 mg tablet Invokamet 150 mg-1,000 mg tablet Invokamet 150 mg-500 mg tablet Invokamet 50 mg-1,000 mg tablet Invokamet 50 mg-500

More information

2016 FORMULARY ADDENDUM NOTICE OF CHANGE

2016 FORMULARY ADDENDUM NOTICE OF CHANGE 2016 FORMULARY ADDENDUM NOTICE OF CHANGE (PRESCRIPTION DRUG PLANS) WELLCARE PRESCRIPTION INSURANCE, INC. WellCare Simple (PDP) WellCare Classic (PDP) WellCare Extra (PDP) This is a listing of the changes

More information

November 2018 P & T Updates

November 2018 P & T Updates November 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth AIMOVIG 3 2 Detailed s 70 mg per month: 2 ml per 60 days 140 mg per month: 2 ml per 30 days AJOVY 3 2 4.5 ml

More information

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review

More information

Drug Formulary Update, April 2013

Drug Formulary Update, April 2013 Drug Formulary Update, April 2013 Updates to the HealthPartners Drug Formularies are listed below. Updates for the Commercial Drug Formularies and the Minnesota Health Care Programs (Medicaid and Minnesota

More information

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS ANTIDIABETIC AGENTS - MISCELLANEOUS GLYXAMBI 10 MG-5 MG GLYXAMBI 25 MG-5 MG INVOKAMET 150 MG-1,000 MG INVOKAMET 150 MG-500 MG INVOKAMET 50 MG-1,000 MG INVOKAMET 50 MG-500 MG INVOKAMET XR 150 MG-1,000 MG,

More information

BlueLink TPA FlexRx Updates

BlueLink TPA FlexRx Updates BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%

More information

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria ANTIDEPRESSANTS Trintellix 10 mg tablet Trintellix 20 mg tablet Trintellix 5 mg tablet Viibryd 10 mg (7)-20 mg (23) tablets in a dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension

More information

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates April 2018 TRADE NAME (generic name) or generic name Brand/Generic Description of Change abacavir sulfate soln 20 mg/ml (base equiv) Generic

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription

More information

Step Therapy Requirements. Effective: 11/01/2018

Step Therapy Requirements. Effective: 11/01/2018 Effective: 11/01/2018 Updated 10/2018 ANTIDEPRESSANTS Sharp Health Plan (HMO) TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET APTIOM 800 MG TABLET BANZEL 200 MG TABLET BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG TABLET FYCOMPA 0.5 MG/ML ORAL SUSPENSION

More information

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Comparison of representative topical corticosteroid preparations (classified according to the US system) Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),

More information

NSAID all (Warner-Schmidt) includes all (NSAIDs, Salicytes, and Cox-2 inhibitors)

NSAID all (Warner-Schmidt) includes all (NSAIDs, Salicytes, and Cox-2 inhibitors) Table S1. Medications categorized as s all (Warner-Schmidt) includes all (s, Salicytes, and Cox-2 inhibitors) Nonsteroidal anti-inflammatory agents Bromfenac Diclofenac Diclofenac-misoprostol Etodolac

More information

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS ANTIDIABETIC AGENTS - MISCELLANEOUS Glyxambi 10 mg-5 mg tablet Glyxambi 25 mg-5 mg tablet Invokamet 150 mg-1,000 mg tablet Invokamet 150 mg-500 mg tablet Invokamet 50 mg-1,000 mg tablet Invokamet 50 mg-500

More information

Step Therapy Requirements. Effective: 05/01/2018

Step Therapy Requirements. Effective: 05/01/2018 Step Therapy Requirements Effective: 05/01/2018 ANTIDEPRESSANTS TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK VIIBRYD 10 MG

More information

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E Santa Clara Family Health Plan Cal MediConnect Formulary List of Step Therapy Requirements Effective: 12/01/2018 13027.12E ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG FYCOMPA 0.5 MG/ML ORAL SUSPENSION FYCOMPA 10 MG FYCOMPA 12 MG FYCOMPA

More information

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details AMANTADINE ER OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE OSMOLEX ER 258 MG TABLET, PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.

More information

2018 Medicare Part D Formulary Change

2018 Medicare Part D Formulary Change 2018 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy

More information

2019 Formulary Update

2019 Formulary Update MEDICARE ADVANTAGE BlueShield of Northeastern New York Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January. This document

More information

ANTIDEPRESSANTS - BUPROPION

ANTIDEPRESSANTS - BUPROPION Step Therapy Paramount Medicare Formulary 2012 Formulary ID 12112, Version 22. CMS Approved 10-23-2012. ANTIDEPRESSANTS - BUPROPION Aplenzin may be given. Step 1 Drug(s): Budeprion Sr, Budeprion Xl, Bupropion

More information

WellCare of South Carolina Preferred Drug List Update

WellCare of South Carolina Preferred Drug List Update WellCare of South Carolina Preferred Drug List Update This is a list of changes to our preferred drug list. These are a result of the latest WellCare Pharmacy & Therapeutics meeting held on August 21,

More information

Step Therapy Requirements

Step Therapy Requirements Step Therapy Requirements Denver Health Medicare Choice (HMO SNP)/Medicare Select (HMO) Effective: 09/01/2017 Updated 08/2017 ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet

More information